Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Table of Contents | Next Article »
Circulation. 1995;93:792-799

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mruk, J. S.
Right arrow Articles by Chesebro, J. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mruk, J. S.
Right arrow Articles by Chesebro, J. H.

(Circulation. 1995;93:792-799.)
© 1995 American Heart Association, Inc.

Articles

Does Antithrombotic Therapy Influence Residual Thrombus After Thrombolysis of Platelet-Rich Thrombus?

Effects of Recombinant Hirudin, Heparin, or Aspirin

Presented in part at the 63rd Scientific Sessions of the American Heart Association, Dallas, Tex, November 12-15, 1990; 40th Annual Scientific Session, American College of Cardiology, Atlanta, Ga, March 3-7, 1991; and 41st Annual Scientific Session, American College of Cardiology, Dallas, Tex, April 12-16, 1992.

Jozef S. Mruk, MD, PhD; Pierre Zoldhelyi, MD; Mark W.I. Webster, MB, CHB; Magda Heras, MD; Diane E. Grill, MS; David R. Holmes, Jr, MD; Valentin Fuster, MD; James H. Chesebro, MD

From the Division of Cardiovascular Diseases and Internal Medicine (J.S.M., P.Z., M.W.I.W., M.H., D.E.G., D.R.H. Jr., J.H.C.), Mayo Clinic and Mayo Foundation, Rochester, Minn; and Mount Sinai Medical Center and School of Medicine (V.F.), New York, NY.

Correspondence to James H. Chesebro, MD, Cardiovascular Institute, Box 1030, Mount Sinai Medical Center, One Gustave L. Levy Pl, New York, NY 10029-6574.


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background Thrombolysis to normal flow in patients with acute myocardial infarction preserves left ventricular function and decreases mortality. Failure of early reperfusion, reocclusion, or residual thrombus may be due to concurrent activation of the platelet-coagulation system. Thus, we hypothesized that the best concomitant antithrombotic therapy (recombinant [r]-hirudin, heparin, or aspirin) will maximally accelerate thrombolysis by r–tissue-type plasminogen activator (rTPA) and reduce residual thrombus.

Methods and Results Occlusive thrombi were formed in the carotid arteries of 29 pigs (by balloon dilatation followed by endarterectomy at the site of injury-induced vasospasm) and matured for 30 minutes before rTPA was started, with or without antithrombotic therapy. Thrombolysis was assessed with the use of angiography and measurement of residual thrombus. Pigs were allocated to one of five treatments: placebo, rTPA, rTPA plus r-hirudin, rTPA plus heparin, or rTPA plus intravenous aspirin. No placebo-treated pig reperfused. Two of six animals treated with rTPA alone reperfused compared with seven of seven animals treated with rTPA plus r-hirudin (reperfusion time, 33±10 minutes), six of seven animals treated with rTPA plus heparin (reperfusion time, 110±31 minutes), and two of six animals with rTPA plus aspirin. The activated partial thromboplastin time was prolonged in only the rTPA plus r-hirudin group (25±0.1 times baseline) and the rTPA plus heparin group (5.3±0.2 times baseline). Residual 111In-platelet and 125I-fibrin(ogen) depositions were lower in the heparin-treated group and lowest in the r-hirudin–treated group (heparin versus hirudin, respectively; incidence of residual macroscopic thrombus was six of six animals versus two of seven [P=.01]; 125I-fibrin(ogen), 170±76 versus 48±6 x106 molecules/cm2 [P=.02]; 111In-platelets, 47±15 versus 13±2 x106/cm2, P=.10). No pigs developed spontaneous bleeding.

Conclusions Thrombin inhibition with heparin or r-hirudin significantly accelerated thrombolysis of occlusive platelet-rich thrombosis, but only the best antithrombotic therapy (r-hirudin) eliminated or nearly eliminated residual thrombus.


Key Words: thrombosis • platelets • fibrin


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Prompt treatment of evolving myocardial infarction with thrombolytic agents improves survival and preserves cardiac function.1 2 3 4 Despite the use of heparin and aspirin, however, recanalization of the occluded coronary artery (which predicts myocardial salvage) is achieved in only 50% to 80% of patients, depending in part on the thrombolytic agent that is used.1 4 5 6 7 Complete reperfusion (TIMI grade 3 flow) at 90 minutes improves 24-hour and 30-day mortality and myocardial function but is achieved in only 29% to 54% of patients.4 Simultaneous ongoing thrombosis appears to limit thrombolysis.8 9 10 11 Because residual thrombus is more thrombogenic than deeply injured artery,12 therapy should target its dissolution.

Activation of coagulation during pharmacological thrombolysis activates platelets, generates thrombin, occurs with both SK and rTPA, and may be mediated by plasmin or SK or directly by rTPA.8 9 10 Thrombin generation during thrombolysis may reflect paradoxical activation of prothrombin,8 13 exposure of coagulantly active thrombin bound to fibrin,14 15 16 17 or both. The rate and extent of thrombolysis are limited, probably by thrombin-related mechanisms.11 18 19

New, specific direct thrombin inhibitors have been more effective than heparin in preventing platelet-dependent thrombosis after arterial injury.20 21 22 23 24 25 Unlike heparin, these agents react directly with thrombin to form enzyme/inhibitor complexes.19 20 24

Because thrombosis and lysis are dynamic and simultaneous processes,11 26 we hypothesized that the best antithrombotic therapy (r-hirudin) at the dose that prevented macroscopic mural thrombus after deep injury21 22 would maximally increase the rate and extent of thrombolysis compared with aspirin, placebo, or heparin. We used the dose of heparin that had a measurable aPTT, reduced mural thrombus, and had previously enhanced thrombolysis in dogs.20 21 26 This dose (200 U/kg over the first hour) is higher than conventional doses of heparin used in coronary care units. Extensive deep arterial injury, with platelet-rich thrombotic occlusion, was created with balloon angioplasty and directional endarterectomy. Major end points were incidence of residual thrombus, quantitative residual 111In-platelet and 125I-fibrin(ogen) depositions, and incidence of and time of reperfusion.


*    Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Twenty-nine 4-month-old pigs (mean weight, 35.0±0.4 kg) of Babcock four-way cross stock (a mixture of Landrace, Yorkshire, Hampshire, and Durock breeds) were assigned to treatment with either placebo (three pigs), rTPA (six pigs), rTPA and r-hirudin (seven pigs), rTPA and heparin (seven pigs), or rTPA and aspirin (six pigs). Drug administration during the experiments was not blinded, but all subsequent data and tissue and sample analyses were performed without knowledge of the treatment administered. The study was approved by the Mayo Clinic Animal Care Committee and conformed with American Heart Association guidelines.

Iodination of Porcine Fibrinogen
Porcine fibrinogen (Sigma Chemical Co) was dissolved in buffer containing 150 mmol/L NaCl, 5 mmol/L trisodium citrate, and 20 mmol/L Tris-HCl, pH 7.4, and was centrifuged at 12 000g for 10 minutes at room temperature to remove insoluble particles. Next, the fibrinogen solution was treated with 5 mmol/L diisopropyl fluorophosphate for 2 hours at 4°C and dialyzed three times for 4 hours at 4°C against 100-fold excess of the buffer. After final dialysis, fibrinogen preparation was again centrifuged at room temperature for 10 minutes at 12 000g. Fibrinogen preparations were more than 92% clottable with thrombin in vitro. After iodination in batches with 125I, fibrinogen solution was stored in aliquots at -70°C until use in each porcine experiment.

Porcine fibrinogen was iodinated with 125I.27 28 More than 93% of the radioactivity of labeled fibrinogen was perceptible with tricholoroacetic acid. Coomassie blue staining and autoradiography of sodium dodecyl sulfate/polyacrylamide gel electrophoresis of iodinated fibrinogen showed a single band on unreduced gels and three bands on the reduced gels. Iodinated fibrinogen was more than 95% clottable with thrombin in vitro.

Platelet Labeling With 111In-Tropolone
Autologous femoral arterial blood (43 mL) was drawn into 7 mL of adenosine/citrate/dextrose anticoagulant and platelets labeled with 111In-tropolone.22 28

Experimental Protocol
One day before surgery, autologous 111In-labeled platelets (300 µCi) and 125I-fibrinogen (250 µCi) were (re)injected into the pigs. On the next day, pigs were sedated with 1000 mg ketamine IM (Ketaset, Bristol Laboratories), intubated, and mechanically ventilated with room air (Harvard respirator, Harvard Apparatus). Anesthesia was maintained with an infusion of etomidate (40 mg/L; Abbott Laboratories), fentanyl (10 mg/L; Abbott), and ketamine (1000 mg/L) at 3 to 5 mL/min. The ECGs and intra-arterial pressures were monitored continuously.

Formation of Carotid Occlusive Thrombus
After general anesthesia and intubation, bilateral femoral cutdowns were performed to expose both femoral arteries and veins. Cannulation was performed in the right femoral artery for continuous arterial pressure monitoring, the right femoral vein for venous blood sampling, the left femoral vein for infusion of drugs, and the left femoral artery for angioplasty catheter access. An 0.8x3-cm balloon dilation catheter (Blue Max, Medi-tech) was advanced to the proximal left carotid artery under fluoroscopic guidance. A standardized dilation protocol was performed of five inflations to 6 atm for 30 seconds, with 60 seconds between inflations. We have previously shown that deep arterial injury (tear through the internal elastic lamina into the media) is created by this protocol in 70% to 80% of dilated arteries.21 22 29 Platelet-rich mural thrombi and, occasionally, occlusive thrombi form over areas of deep arterial injury. Severe vasospasm always occurs immediately distal to the balloon-induced deep injury site.29 30 The area of vasospasm (approximately 5 cm from the bifurcation of the carotid arteries) was identified, marked on the skin with metallic clips, and used to create a localized consistent area of deep arterial injury, with increased flow, velocity, and shear rate. An 11F guiding sheath, with side holes to maintain blood flow, was placed in the proximal left carotid artery, and Simpson's directional endarterectomy device (AtheroCath, Devices for Vascular Intervention) was positioned at the level of the distal vasospasm. Six longitudinal endarterectomy cuts (approximately 1.5x9 mm), with 60° rotation between each pass, resulted in consistent, localized injury in the media. Occlusive platelet-rich thrombi formed within minutes over the area of endarterectomy.

Before arterial injury, each pig received a bolus of 25 U/kg heparin to prevent clotting on the catheters and stasis thrombosis caused by the 11F guiding sheath. The biological half-life of this dose of heparin in pigs is approximately 12 minutes, and platelet deposition at the site of deep arterial injury is not significantly affected.21 31 After endarterectomy, the Simpson's device and guiding sheath were withdrawn. The thrombus was allowed to mature for 30 minutes, and a 7F right Judkins diagnostic angiographic catheter (Cordis) with a metallic ring marker for calibration was placed just distal to the carotid bifurcation. To exclude occlusion of the left carotid artery secondary to vasospasm, nitroglycerin (300 µg over 1 minute) was injected into the proximal left carotid artery at the end of the thrombus maturation period. Lack of blood flow by contrast angiography after nitroglycerin injection indicated that the filling defect was caused by occlusive thrombus and not by vasospasm.

Time to Reperfusion
Carotid angiography was performed with 6 mL of ionic contrast (Renographin 76, Squibb). Spot films were taken before angioplasty, immediately after angioplasty, after 30 minutes of thrombus maturation, and after nitroglycerin administration. During the subsequent infusions of thrombolytic regimens (or placebo), angiograms of the left carotid artery were performed every 10 minutes for the first 90 minutes and then every 30 minutes for the next 120 minutes. The study protocol is summarized in Fig 1Down.



View larger version (17K):
[in this window]
[in a new window]
  		Figure 1. Experimental design for formation of occlusive thrombus in porcine carotid artery, timing for administration of treatment, and timing and contrast angiographic observations (arrows).

Treatment Administration
R-Alteplase (single-chain rTPA, Genetech, Inc) was given as a bolus of 0.3 mg/kg, followed by a continuous infusion of 2 mg/kg per hour for the first 90 minutes and then at 0.5 mg/kg per hour for the next 120 minutes. On the basis of previous dose-ranging studies,22 r-desulfato-hirudin (CGP 39393, CIBA-GEIGY Pharmaceuticals) was administered at the lowest infusion dose that prevented thrombus (bolus, 1 mg/kg; infusion, 0.7 mg/kg per hour for 210 minutes). On the basis of dose-ranging study of six heparin doses,21 heparin from porcine intestine (Elkins-Sinn, Inc) was administered at the lowest dose that reduced platelet-rich thrombus (bolus, 100 U/kg; infusion, 100 U/kg per hour for 210 minutes). Heparin or r-hirudin was started at the same time as rTPA. L-Lysine acetylsalicylic acid (Bayer) equivalent to 5 mg/kg of acetylsalicylic acid (aspirin) was administered as an intravenous bolus 15 minutes before rTPA infusion. This dose of aspirin completely inhibited aggregation of porcine platelets induced by arachidonic acid in whole blood.32 33

Tissue Preparation and Analysis
At 210 minutes after the start of treatment, 120 mL of filtered 0.5% Evans blue dye solution (Sigma) in 0.9% saline was injected into the descending aorta to demarcate the extent of arterial injury. After the pigs were killed with an overdose of pentobarbital, the proximal descending aorta was immediately cannulated and the carotid arteries were perfused with buffered 0.9% saline until the effluent from external jugular vein incisions was clear. The vessels were then perfused with buffered 2% glutaraldehyde for 15 minutes. All perfusions were done at physiological pressure. After fixation in situ, the carotid arteries were harvested and cleaned of adventitia. The area of injury of the left carotid artery was documented by sketches on a 1:1 scale and cut into 1-cm segments for subsequent analysis: isotope counting and macroscopic and microscopic examinations. Platelet and fibrin(ogen) depositions on arterial segments were quantified according to the method of Dewanjee.28 Counting for 111In was performed on the day of surgery and, for 125I, 3 weeks later, as previously described.21 22 In segments positive for Evans blue dye staining or thrombus, at least two histological sections per segment were stained with van Gieson's elastic and hematoxylin and eosin stains and examined with light microscopy for deep injury. Each artery was examined for macroscopic thrombus with a 2x magnifier as previously described.21 22 29

Hemostatic Parameters
Blood samples for hemostatic measurements (anticoagulated with 0.13 mol/L trisodium citrate; ratio of anticoagulant to blood, 1:10) were drawn via two-syringe technique before and 90 minutes after the start of treatment and immediately before the animals were killed at 210 minutes. Platelet counts, hematocrits, and aPTTs were determined with the use of standard methods as previously described.21 22 Samples for fibrinogen levels were supplemented with aprotinin (200 IU/mL blood, Sigma).34 35 Plasma samples for fibrinogen determination were stored at -70°C. Plasma fibrinogen was measured in batches as described by Jacobsson.36 Thrombin-clottable plasma protein (fibrinogen) was determined after collection of clots on wooden applicator sticks and subsequent solubilization, using the biuret method (Total Protein Kit, Sigma).37 38

Fibrinolytic Activity of rTPA, UK, and SK Against Human and Porcine Plasminogen-Rich Fibrin
Fibrinolytic activity was measured according to the fibrin plate lysis method as described by Haverkate and Brakman.39 Drops (35 µl) of each concentration of fibrinolytic agents were applied, and fibrin plates were incubated for 18 hours at 37°C at 100% relative humidity.39 40 41 rTPA (it was assumed that 2 ng rTPA=1 IU)42 43 was obtained from Genetech, Inc; UK (Abbokinase) was from Abbott Laboratories; and SK (Streptase) was from Hoechst-Russel Pharmaceuticals, Inc. Fibrinolytic reagents were dissolved as recommended by the manufacturers, divided into small aliquots, and stored at -70°C. For experiments, stock solutions of fibrinolytic reagents were diluted to the desired concentrations with gelatin buffer.39 Human plasminogen-rich fibrinogen (Grade-L) was obtained from Kabi-Vitrum Inc, and bovine thrombin (Thrombinar) was obtained from Jones Medical Industries. Porcine plasminogen-rich fibrinogen was obtained from Sigma Chemical Co, and all other reagents were from Sigma or Fisher Scientific Co and were the highest available quality.

Plasminogen content in porcine and human fibrinogens was determined by incubating solutions of fibrinogens with 1000 U/mL UK for 2 hours at 37°C to allow activation of plasminogen to plasmin. Standard curves were constructed activating the porcine and human plasminogens (Sigma) under the same conditions. Plasmin activities were determined with the chromogenic substrate Spectrozyme PL (American Diagnostica Inc). Plasminogen content of porcine fibrinogen (42.5 µg/mg fibrinogen) was similar to human fibrinogen (32 µg/mg fibrinogen).

Statistical Analysis
Results are presented as mean±SEM. The three animals in the placebo group were not included in any analyses. Residual platelets and molecules of fibrin(ogen) per centimeter squared of artery were analyzed after a logarithmic transformation was applied to normalize the data. One-way ANOVA was used to test for any differences between all of the treatment groups in residual platelets, molecules of fibrin(ogen) per cm2 of artery, hematocrit, platelet counts, and fibrinogen. When the one-way ANOVA was statistically significant (P<.05), the Student's t test was used for pairwise group comparisons. Because the time until reperfusion did not have a normal distribution, a Kruskal-Wallis test was used to test for an overall group difference. The Wilcoxon rank-sum test was then used to compare groups.


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Fibrinolytic Activity of rTPA, UK, and SK Against Human and Porcine Plasminogen-Fibrin In Vitro
Dosing of rTPA was based on in vitro determinations of fibrinolytic activity (Fig 2Down). SK did not activate porcine plasminogen. Porcine plasminogen was approximately 10-fold more resistant to activation by rTPA than was human plasminogen, necessitating higher doses of rTPA for porcine than for human studies.



View larger version (20K):
[in this window]
[in a new window]
  		Figure 2. Fibrinolytic activity in vitro of rTPA ({circ}), UK ({triangleup}), and SK ({square}) against human (open symbols) and porcine (closed symbols) plasminogen-rich fibrin. (Note: SK does not activate porcine plasminogen.72 )

Outcome and Reperfusion
Times to reperfusion are summarized in Fig 3Down. No animal reperfused in the placebo group. Of six animals treated with rTPA alone, one reperfused at 90 minutes and one reperfused at 120 minutes (mean, 105 minutes). Macroscopic and microscopic examinations of the injured carotid arteries confirmed the presence of a platelet-rich occlusive thrombi overlying an area of deep arterial injury. Typically, platelet thrombi were coated with a fibrin- and erythrocyte-rich layer. The pig that reperfused at 90 minuets died suddenly at 120 minutes. Necropsy did not show hemorrhagic or embolic complications.



View larger version (39K):
[in this window]
[in a new window]
  		Figure 3. Time to reperfusion of occluded carotid arteries in control and treated groups. Each horizontal bar represents one pig with occlusion (shaded) and patency (open) indicated over time. n indicates number of animals. Mean aPTT ratios to control ±SEM are listed for each group.

In the rTPA-plus-heparin group, six of seven pigs reperfused (at 10, 70, 70, 120, 180, and 210 minutes; mean, 110 minutes). After reperfusing at 70 minutes, one pig reoccluded and developed a large perivascular hematoma of the neck at 120 minutes, secondary to carotid artery perforation, resulting in airway compromise and termination of the study at 180 minutes. The second pig that reperfused at 70 minutes died suddenly at 150 minutes. No hemorrhagic or embolic complications were found on necropsy.

Of seven animals treated with rTPA and r-hirudin, all reperfused (at 10, 10, 30, 40, 40, 50, and 50 minutes; mean, 33 minutes), and two transiently reoccluded but reopened. None had hemorrhagic complications during the 210 minutes of study.

Reperfusion occurred in only two of six pigs receiving adjunctive aspirin treatment with rTPA: one at 60 minutes and the other at 80 minutes. The former animal died suddenly at 180 minutes (unremarkable necropsy); the latter reoccluded at 150 minutes and did not reperfuse again.

Residual Thrombus, Platelets, and Fibrin(ogen)
Fig 4ADown and 4BDown summarizes platelet and fibrin(ogen) deposition in the left carotid arteries. Residual 111In-platelet deposition was 355±106, 123±23, 13±2, 47±15, and 328±96 x10-6/cm2 with placebo, rTPA alone, rTPA plus hirudin, rTPA plus heparin, and rTPA plus aspirin, respectively. Residual 125I-fibrin(ogen) deposition x1012 molecules/cm2 was 1712±503, 714±261, 48±6, 170±76, and 1389±246 in the same respective groups as 111In-platelet deposition. Statistical differences between groups are summarized in Fig 4ADown and 4BDown.



View larger version (40K):
[in this window]
[in a new window]
  		Figure 4. A, Residual 111In-platelet deposition per cm2 at the end of 210 minutes of treatment. Bar indicates the mean value; vertical line, SEM; and n, number of pigs in each treatment group. B, Residual 125I-fibrin(ogen) deposition per cm2 at the end of 210 minutes of treatment. Bar indicates mean value; vertical line, SEM; and n, number of pigs in each treatment group.

In the rTPA group, both of the animals that reperfused had marked mural thrombus at euthanasia. In the rTPA-plus-aspirin group, both of the two reperfused pigs had extensive mural thrombi. All six reperfused pigs receiving rTPA plus heparin had residual thrombi (marked in five and minimal in one) at necropsy. In contrast, no thrombus was found in five pigs, and only minimal residual macroscopic mural thrombus was found in two of seven reperfused pigs receiving rTPA plus r-hirudin (P=.01 versus heparin). Representative angiograms of residual arterial obstruction in pigs receiving adjuvant therapy are shown in Fig 5Down (note improved patency after administration of rTPA plus r-hirudin).



View larger version (127K):
[in this window]
[in a new window]
  		Figure 5. Representative angiograms of left carotid artery in pigs treated with rTPA alone (left), rTPA plus heparin (middle), and rTPA plus r-hirudin (right). Note long segments with extensive residual irregular thrombus in both non–hirudin-treated pigs and clear lumen in hirudin-treated pigs.

Hemostatic Parameters
In all groups, the hematocrit and platelet count decreased slightly but not significantly at 210 minutes or death. The aPTT remained normal throughout the experiments in the control, rTPA, and rTPA-plus-aspirin groups. In the rTPA–plus–r-hirudin group, the aPTT was prolonged to 2.5±0.1 times baseline control value at 90 minutes and to 2.7±0.2 times baseline control at 210 minutes. In the rTPA-plus-heparin group, the aPTT was prolonged to 5.3±0.6 and 7.3±0.5 times baseline control at 90 minutes and at 210 minutes, or death, respectively.


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
This is the first report of quantitative measurement of residual thrombus burden after thrombolysis. Direct thrombin inhibition with r-hirudin, compared with heparin, significantly accelerated the rate and extent of lysis of occlusive platelet-rich thrombi by rTPA after deep arterial injury in the pig; r-hirudin eliminated residual thrombus in five of seven pigs compared with none of six pigs receiving heparin (P=.01). Fibrin(ogen) deposition was also greater in heparin- than in hirudin-treated pigs (P=.02). r-Hirudin was used at an aPTT of only 2.5 times control (clinically acceptable with lytic agent) compared with heparin at an aPTT of 5.3 times control (clinically unacceptable with lytic agent). aPTTs have a unique relation to the blood level of each thrombin inhibitor and do not indicate the antithrombotic efficacy.44 However, high aPTTs (>3 times control) in humans receiving lytic therapy are associated with an increased incidence of intracerebral bleeds.45 46 Both heparin and r-hirudin significantly decreased residual platelet and fibrin(ogen) deposition after lysis compared with aspirin or rTPA alone. In all seven pigs receiving rTPA plus r-hirudin, all carotid arteries were open by 50 minutes, and all remained widely patent at 210 minutes, with only minimal residual thrombus in two.

No spontaneous bleeding was observed in any of the pigs. Dosing of heparin and hirudin was based on prior dose-ranging studies to find the lowest dose reducing or eliminating thrombus.21 22 The bolus dose rapidly increased the aPTT and blood level to plateau but not above21 22 to minimize the risk for bleeding. In human studies in which bleeding resulted with r-hirudin and thrombolysis, the aPTT after the bolus dose significantly exceeded the subsequent plateau level.45 46

The increased rate and extent of lysis for normal early reflow (TIMI grade 3 flow) appear to be critical for reduced mortality and improved myocardial function.4 Because rehospitalization for angina, reinfarction, and revascularization over the next year occurs in more than 50% of patients,47 reduced thrombus burden (shown to be feasible in this study) in patients may reduce these clinical events.

Thrombin is pivotal for the formation, growth, maintenance, and consolidation of thrombus. Direct inhibition with r-hirudin (a specific probe for thrombin), but not heparin, blocks these processes and leads to dissolution of thrombus.12 20 21 22 48 49 Reasons for the powerful protective effect of hirudin over heparin may relate to active thrombin binding to fibrin and arterial wall substrates, which causes conformational changes in thrombin and poor binding by heparin/antithrombin III but no change in binding by hirudin.17 50 In addition, platelet secretion and fibrin formation produce natural inhibitors of heparin action but no inhibitors against hirudin.51 52 53 54 Substantial amounts of thrombin remain bound to fibrin in thrombus.14 15 16 17 Heparin is 20 to 50 times less effective than r-hirudin in inhibiting thrombin bound to fibrin compared with thrombin in solution.17 This probably occurs because receptors on fibrin-bound thrombin are masked for binding to heparin/antithrombin III and heparin/heparin cofactor II. In addition, platelet factor 4 (released from platelets) and generated fibrin monomer II interfere with heparin and heparin/antithrombin III action.50 51 52 53 54 Antithrombins with greater binding affinity to thrombin have greater antiplatelet potential and at lower anticoagulant dosage (lower aPTT). Graded reduction in thrombin affinity of r-hirudin mutants resulted in a progressive attenuation of antiplatelet activity with no change in inhibition of fibrin formation and was not reflected by measurement of the aPTT.55 Thrombin inhibitors with lower binding affinities have not prevented mural thrombus in deeply injured arteries, even at high doses that result in very prolonged aPTTs.55

Clinical data indicate that after lytic therapy for acute myocardial infarction, concomitant aspirin plus heparin therapy to an aPTT of 60 to 85 seconds is associated with very low reocclusion rates (4.9% to 6.4%) 1 week after thrombolysis4 and is dependent on the level of anticoagulation.18 56 57 58 The pilot study of r-hirudin versus heparin for thrombolysis in acute myocardial infarction supports the superiority of r-hirudin over heparin plus aspirin in improving early reflow and reducing reocclusion, ischemic pain, reinfarction, or death.56 The median delay of 40 minutes in starting randomized therapy with r-hirudin or heparin after thrombolytic therapy in TIMI 9 requires analysis and may account for no difference between therapies.59

Aspirin did not reduce the time to reperfusion or platelet or fibrin(ogen) deposition compared with rTPA alone. With thrombus as a substrate for thrombosis, aspirin alone or added to heparin did not reduce growth of thrombus.12 Asprin has a borderline effect on rethrombosis after thrombolysis in dogs.9 60 Aspirin dramatically improves the overall outcome of thrombolytic therapy in large clinical trials.2 18 Decreased reocclusion probably plays a major role because aspirin does not appear to accelerate thrombolysis, time to reperfusion after deep arterial injury, or platelet-rich arterial thrombosis, as suggested by a meta-analysis and shown by this study.61 The central core of the thrombus contains much less stainable thrombin than thrombus adjacent to deeply injured artery.62 This may explain the reduction in reocclusion but not mural thrombus by aspirin.

Heparin at the dosage used in this study reduced the incidence of mural thrombus to 25% after deep injury compared with 76% with placebo in the prior dose-ranging studies.21 22 Cercek et al26 first reported the acceleration of arterial thrombolysis with rTPA by pretreating dogs with 200 U/kg heparin. Acceleration of thrombolysis by heparin in dogs was later seen with pro-urokinase,63 SK, and UK.64 Choice of a fibrin-rich arterial thrombus model (coronary copper coil) and choice of a species that responds to low levels of plasminogen activators (dog)26 make comparison with our study difficult. Disrupted human plaques produce large platelet-rich thrombi at the injury site and fibrin-erythrocyte–rich distal or proximal extensions.65 66 67 Platelet-rich thrombi are relatively resistant to plasminogen activators68 69 and also require higher levels of hirudin for prevention.61 70 Thus, dose-response depends in part on type of injury, type of thrombus, and species.

The effects of heparin at this dose on other coagulation proteases, such as factor Xa, are of less physiological importance than thrombin.71 72 In addition, administration of rTPA with lower-dose r-hirudin (aPTT of 1.5 to 2.0 times control) in dogs with coronary thrombosis induced by electrical (mild) injury accelerated lysis and prevented reocclusion, whereas heparin at doses with similarly low aPTTs did not accelerate lysis and prevented reocclusion.60

In summary, the best antithrombotic therapy (inhibition of thrombin by r-hirudin) not only accelerates thrombolysis but also eliminates or reduces residual platelet-rich thrombus after deep arterial injury. The high dose of heparin required for reduction of mural thrombus and acceleration of thrombolysis produces an excessive prolongation of the aPTT (5 to 6 times control) for routine clinical use. However, direct thrombin inhibition by r-hirudin at a dose that prolonged the aPTT to a clinically relevant 2.5 times control accelerated thrombolysis with rTPA, almost completely eliminated residual thrombus, and appears promising for treatment in humans.


*    Selected Abbreviations and Acronyms
 
aPTT = activated partial thromboplastin time
r = recombinant
SK = streptokinase
TPA = tissue-type plasminogen activator
UK = urokinase


View this table:
[in this window]
[in a new window]
  		Table 1. Platelet and Fibrin(ogen) Deposition


*    Acknowledgments
 
Dr Mruk was the recipient of a fellowship from NIH (HL-07111/14T); Dr Webster was the recipient of a fellowship from the National Heart Foundation of New Zealand and the Fogarty Center, NIH; Dr Heras was the recipient of a research grant from CIRIT, Generalitat de Catalunya, Spain; and Dr Chesebro was funded in part by NIH grant HL-39959.

Received November 9, 1994; revision received August 24, 1995; accepted September 25, 1995.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. Gruppo Italiano Per Lo Studio Della Streptochinasi Nell-Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402. [Medline] [Order article via Infotrieve]
  2. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs antistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 1993;339:753-770.
  3. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682. [Abstract/Free Full Text]
  4. The GUSTO Angiographic Investigators. An angiographic study within the global randomized trial of aggressive versus standard thrombolytic strategies in patients with acute myocardial infarction. N Engl J Med. 1993;329:1615-1622. [Abstract/Free Full Text]
  5. Marder VJ, Sherry S. Thrombolytic therapy: current status (two parts). N Engl J Med. 1988;318:1512-1520, 1585-1595. [Medline] [Order article via Infotrieve]
  6. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hills D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76:142-154. [Abstract/Free Full Text]
  7. Guerci AD, Gerstenblith G, Brinker JA, Chandra NC, Gottlieb SO, Bahr RD, Weiss JL, Shapiro EP, Flaherty JT, Bush DE. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med. 1987;317:1613-1618. [Abstract]
  8. Winters KJ, Santoro SA, Miletich JP, Eisenberg PR. Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase. Circulation. 1991;84:1552-1560. [Abstract/Free Full Text]
  9. Fitzgerald DJ, Wright F, FitzGerald GA. Increased thromboxane biosynthesis during coronary thrombolysis: evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res. 1989;65:83-94. [Abstract/Free Full Text]
  10. Eisenberg PR, Sherman L, Rich M, Schwartz D, Schechtman K, Geltman EM, Sobel BE, Jaffe AS. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol. 1986;7:1255-1262. [Abstract]
  11. Chesebro JH, Fuster V. Dynamic thrombosis and thrombolysis: role of antithrombins. Circulation. 1991;83:1815-1817. [Free Full Text]
  12. Meyer BJ, Badimon JJ, Mailhac A, Fernandez-Ortiz A, Chesebro JH, Fuster V, Badimon L. Inhibition of growth of thrombus on fresh mural thrombus: targeting optimal therapy. Circulation. 1994;90:2432-2438. [Abstract/Free Full Text]
  13. Lee DC, Mann KD. Activation/inactivation of human factor V by plasmin. Blood. 1989;73:185-190. [Abstract/Free Full Text]
  14. Seegers WH, Nieft M, Loomis EC. Note on the adsorption of thrombin on fibrin. Science. 1945;101:520-521. [Free Full Text]
  15. Bloom AL. The release of thrombin from fibrin by fibrinolysin. Br J Haemost. 1962;8:129-133.
  16. Mirshahi M, Soria J, Soria C, Faivre R, Lu H, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. Blood. 1989;74:1025-1030. [Abstract/Free Full Text]
  17. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
  18. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1990;323:1433-1437. [Abstract]
  19. Mruk JS, Chesebro JH, Webster WMI. Platelet aggregation and interaction with the coagulation system: implications for antithrombotic therapy in arterial thrombosis. J Coron Artery Dis. 1990;1:149-158.
  20. Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci U S A. 1988;85:3184-3188. [Abstract/Free Full Text]
  21. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation. 1989;79:657-665. [Abstract/Free Full Text]
  22. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJW, Badimon L, Fuster V. Hirudin, heparin and placebo during arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis. Circulation. 1990;82:1476-1484. [Abstract/Free Full Text]
  23. Yao S-K, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. Circulation. 1992;86:1993-1999. [Abstract/Free Full Text]
  24. Collen D, Matsuo O, Stassen JM, Kettner C, Shaw E. In vivo studies of a synthetic inhibitor of thrombin. J Lab Clin Med. 1982;99:76-83. [Medline] [Order article via Infotrieve]
  25. Jang I-K, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation. 1990;81:219-225. [Abstract/Free Full Text]
  26. Cercek B, Lew AS, Hod H, Yano J, Reddy NKNR Ganz. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation. 1986;74:583-587. [Abstract/Free Full Text]
  27. Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3{alpha}-diphenylglycouril. Biochem Biophys Res Commun. 1978;80:849-857. [Medline] [Order article via Infotrieve]
  28. Dewanjee MK. Methods of assessment of thrombosis in vivo. Ann N Y Acad Sci. 1987;516:541-571. [Abstract]
  29. Steele PM, Chesebro JH, Stanson AW, Holmes DR, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty: natural history of the pathophysiologic response to injury in a pig model. Circ Res. 1985;57:105-112. [Abstract/Free Full Text]
  30. Lam JYT, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury: a new antithrombotic role for an old drug. Circulation. 1988;78:712-716. [Abstract/Free Full Text]
  31. Andrew M, Ofosu F, Schmidt B, Brooker L, Hirsh J, Buchanan MR. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thromb Res. 1988;52:517-527. [Medline] [Order article via Infotrieve]
  32. Bochner F, Siebert DM, Rodgers SE, McIntosh GH, James MJ, Lloyd JV. Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. Thromb Haemost. 1989;61:211-216. [Medline] [Order article via Infotrieve]
  33. Galvez A, Badimon L, Badimon JJ, Fuster V. Electric aggregometry in whole blood from human pig and rabbit. Thromb Haemost. 1986;56:128-132. [Medline] [Order article via Infotrieve]
  34. Fears R, Ferres H, Greenwood H. An investigation of methods to prevent fibrinogen degradation during processing of plasma samples containing the fibrinolytic agents, APSAC and t-PA. Fibrinolysis. 1989;3:45-49.
  35. Stump DC, Topol EJ, Chen AB, Hopkins A, Collen D. Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator. Thromb Haemost. 1988;59:133-137. [Medline] [Order article via Infotrieve]
  36. Jacobsson K. Studies on the determination of fibrinogen in human blood plasma. Scand J Clin Lab Invest. 1955;7:1-54.
  37. Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reagent. J Biol Chem. 1949;177:751. [Free Full Text]
  38. Doumas BT, Bayse DD, Carter RJ, Peters T Jr, Schaffer R. A candidate reference method for determination of total protein in serum, I: development and validation. Clin Chem. 1981;27:1642-1650. [Abstract/Free Full Text]
  39. Haverkate F, Brakman P. Fibrin plate assay. Prog Chem Fibrinol Thromb. 1975;1:151-159.
  40. Kluft C. Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators. Thromb Haemost. 1979;41:365-383. [Medline] [Order article via Infotrieve]
  41. Jespersen J, Astrup T. A study of the fibrin plate assay of fibrinolytic agents. Haemostasis. 1983;13:301-315. [Medline] [Order article via Infotrieve]
  42. Gaffney PJ, Curtis AD. A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA). Thromb Haemost. 1985;53:134-136. [Medline] [Order article via Infotrieve]
  43. Rånby M. On the properties of the international standards for tissue plasminogen activator. Thromb Haemost. 1990;63:139. Letter. [Medline] [Order article via Infotrieve]
  44. Hassinger NL, McBane RD, Mruk JS, Zoldhelyi P, Grill DE, Chesebro JH. All thrombin inhibitors are not created equal: the paradox of anticoagulant versus antithrombotic efficacy. Thromb Haemost. 1993;69:888.
  45. GUSTO IIa Investigators. A randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637. [Abstract/Free Full Text]
  46. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation. 1994;90:1624-1630. [Abstract/Free Full Text]
  47. Rogers WJ, Babb JD, Baim DS, Chesebro JH, Gore JM, Roberts R, Williams DO, Frederick M, Passamani ER, Braunwald E, for the TIMI II Investigators. Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. J Am Coll Cardiol. 1991;17:1007-1016. [Abstract]
  48. Wysokinski WE, McBane RD, Hassinger ML, Stewart ML, Chesebro JH, Owen WG. `Dethrombosis': effect of thrombin inhibition on thrombus propagation and maintenance. Thromb Haemost. 1993;69:692. Abstract.
  49. Zoldhelyi P, Chesebro JH, Owen WG. Hirudin as a molecular probe for thrombin in vitro and during systemic coagulation in the pig. Proc Natl Acad Sci U S A. 1993;90:1819-1823. [Abstract/Free Full Text]
  50. Weitz JI, Hudoba M. Mechanism by which clot-bound thrombin is protected from inactivation by fluid-phase inhibitors. Circulation. 1992;86(suppl I):I-413. Abstract.
  51. Bock PE, Luscombe M, Marshall SE, Pepper DS, Holbrook JJ. The multiple complexes formed by the interaction of platelet factor 4 with heparin. Biochem J. 1980;191;769-776.
  52. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci U S A. 1989;86:3619-3623. [Abstract/Free Full Text]
  53. Hogg PJ, Jackson CM. Heparin promotes the binding of thrombin to fibrin polymer: quantitative characterization of a thrombin-fibrin polymer-heparin ternary complex. J Biol Chem. 1990;265:241-247. [Abstract/Free Full Text]
  54. Hogg PJ, Jackson CM. Formation of a ternary complex between thrombin, fibrin monomer, and heparin influences the action of thrombin on its substrates. J Biol Chem. 1990;265:248-255. [Abstract/Free Full Text]
  55. Markwardt F, Stürzebecher J, Glusa E. Antithrombin effects of native and recombinant hirudins. Biomed Biochim Acta. 1990;49:399-404. [Medline] [Order article via Infotrieve]
  56. Cannon CP, McCabe CH, Henry TD, Schweiger M, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol. 1994;23:993-1003. [Abstract]
  57. Arnout J, Simoons M, de Bono D, Rapold JH, Collen D, Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol. 1992;20:513-519. [Abstract]
  58. Zeymer U, Jessel A, Neuhaus K-L. Hirudin as conjunctive therapy in patients with thrombolysis for acute myocardial infarction produced stable prolongation of ACT and APTT. Circulation. 1993;88(suppl I):I-201. Abstract.
  59. Antman EM. Antiplatelet/Antithrombotic Agents [audiotape or videotape]. Dallas, Tex: American Heart Association Inc; 1995. Presented at the 68th Scientific Sessions of the American Heart Association; November 13, 1995; Anaheim, Calif.
  60. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation. 1991;83:1048-1056. [Abstract/Free Full Text]
  61. Roux S, Christeller S, Lüdin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol. 1992;19:671-677. [Abstract]
  62. Chesebro JH, Webster MWI, Zoldhelyi P, Roche PC, Badimon L, Badimon JJ. Antithrombolytic therapy in the progression of coronary artery disease: antiplatelet versus antithrombins. Circulation. 1992;86(suppl III):III-100-III-110.
  63. Susawa T, Yui Y, Hattori R, Takatsu Y, Yui N, Takahashi M, Aoyama T, Murohara T, Shirotani M, Kawai C. Enhancement of coronary thrombolysis with plasminogen proactivator by pretreatment with heparin. Jpn Circ J. 1987;52:72-78.
  64. Cercek B, Lew AS, Satoh Y, Isojima K, Laramee P, Yano J, Yano J, Reddy KNN, Masddahi J, Ganz W. Heparin enhances experimental thrombolysis by preventing new fibrin deposition. Circulation. 1985;72(suppl III):III-194. Abstract.
  65. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82(suppl II):II-38-II-46.
  66. Friedman MF, Van der Bovenkamp EJ. The pathogenesis of a coronary thrombus. Am J Pathol. 1966;48:19-44. [Medline] [Order article via Infotrieve]
  67. Fernandez-Ortiz A, Badimon JJ, Folk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562-1569. [Abstract]
  68. Jang I, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation. 1990;81:219-225.
  69. Loscalzo J, Vaughan DE. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest. 1987;79:1749-1755.
  70. Markwardt F, Kaiser B, Novak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res. 1989;54:377-388. [Medline] [Order article via Infotrieve]
  71. Ofosu FA, Hirsh J, Esmon CT, Modi GJ, Smith LM, Anvari N, Buchanan MR, Fenton JW, Blajchman MA. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa. Biochem J. 1989;257:143-150. [Medline] [Order article via Infotrieve]
  72. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Fuster V. Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury. Arterioscler Thromb. 1992;12:250-255. [Abstract/Free Full Text]
  73. Niewiarowski S, Latallo Z. Comparative studies of the fibrinolytic system of sera of various vertebrates. Thromb Diath Haemosrrh. 1959;3:404-417.



This article has been cited by other articles:


Home page
 CLIN APPL THROMB HEMOSTHome page
H. Luciardi, S. Berman, J. Muntaner, F. De La Serna, and R. Altman
Facilitated Thrombolysis: Dethrombosis?
Clinical and Applied Thrombosis/Hemostasis, April 1, 2002; 8(2): 133 - 138.
[Abstract] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. A. Merlini, D. Ardissino, R. D. Rosenberg, E. Colombi, P. Agricola, L. Oltrona, F. Ottani, M. Galvani, K. A. Bauer, B. Bottasso, et al.
In Vivo Thrombin Generation and Activity During and After Intravenous Infusion of Heparin or Recombinant Hirudin in Patients With Unstable Angina Pectoris
Arterioscler. Thromb. Vasc. Biol., September 1, 2000; 20(9): 2162 - 2166.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. Peter, J. Graeber, S. Kipriyanov, M. Zewe-Welschof, M. S. Runge, W. Kubler, M. Little, and C. Bode
Construction and Functional Evaluation of a Single-Chain Antibody Fusion Protein With Fibrin Targeting and Thrombin Inhibition After Activation by Factor Xa
Circulation, March 14, 2000; 101(10): 1158 - 1164.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. S. Mruk, M. W. I. Webster, M. Heras, J. M. Reid, D. E. Grill, and J. H. Chesebro
Flavone-8-Acetic Acid (Flavonoid) Profoundly Reduces Platelet-Dependent Thrombosis and Vasoconstriction After Deep Arterial Injury In Vivo
Circulation, January 25, 2000; 101(3): 324 - 328.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. Riesbeck, D. Chen, G. Kemball-Cook, J. H. McVey, A. J. T. George, E. G. D. Tuddenham, A. Dorling, and R. I. Lechler
Expression of Hirudin Fusion Proteins in Mammalian Cells : A Strategy for Prevention of Intravascular Thrombosis
Circulation, December 15, 1998; 98(24): 2744 - 2752.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
B. J. Meyer, J. J. Badimon, J. H. Chesebro, J. T. Fallon, V. Fuster, and L. Badimon
Dissolution of Mural Thrombus by Specific Thrombin Inhibition With r-Hirudin : Comparison With Heparin and Aspirin
Circulation, February 24, 1998; 97(7): 681 - 685.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. H. Chesebro
Direct Thrombin Inhibition Superior to Heparin During and After Thrombolysis : Dose, Duration, and Drug
Circulation, October 7, 1997; 96(7): 2118 - 2120.
[Full Text]

Home page
 CirculationHome page
E. M. Antman
Hirudin in Acute Myocardial Infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial
Circulation, September 1, 1996; 94(5): 911 - 921.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions